Organogenesis (NASDAQ:ORGO) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Organogenesis (NASDAQ:ORGO) issued its quarterly earnings data on Thursday. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11, Zacks reports. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.05%. The firm had revenue of $150.86 million during the quarter, compared to the consensus estimate of $134.10 million. Organogenesis updated its FY 2025 guidance to EPS.

Organogenesis Price Performance

Shares of ORGO stock traded up $1.74 during mid-day trading on Friday, hitting $5.63. The company had a trading volume of 32,983,255 shares, compared to its average volume of 722,316. The stock’s 50 day moving average price is $4.43 and its 200-day moving average price is $4.19. Organogenesis has a 52-week low of $2.61 and a 52-week high of $6.71.

Institutional Investors Weigh In On Organogenesis

Large investors have recently made changes to their positions in the company. Walleye Capital LLC bought a new position in Organogenesis during the second quarter valued at approximately $45,000. Creative Planning raised its holdings in Organogenesis by 84.5% during the 2nd quarter. Creative Planning now owns 35,392 shares of the company’s stock valued at $130,000 after buying an additional 16,205 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Organogenesis by 590.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 23,655 shares of the company’s stock worth $87,000 after purchasing an additional 20,228 shares during the period. Raymond James Financial Inc. boosted its position in shares of Organogenesis by 5.7% during the second quarter. Raymond James Financial Inc. now owns 444,240 shares of the company’s stock valued at $1,626,000 after buying an additional 23,919 shares during the period. Finally, Strs Ohio bought a new position in Organogenesis in the 1st quarter valued at $105,000. 49.57% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ORGO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Organogenesis in a report on Wednesday, October 8th. BTIG Research reaffirmed a “buy” rating and set a $7.00 price objective on shares of Organogenesis in a research report on Friday, September 26th. Cantor Fitzgerald boosted their price objective on Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.33.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.